- Home
- ODTX vs NFJ Comparison
ODTX vs NFJ Comparison
Compare ODTX & NFJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ODTX | NFJ |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2025 | 2003 |
Fundamental Metrics
Financial Performance| Metric | ODTX | NFJ |
|---|---|---|
| Price | $19.17 | $14.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $35.33 | N/A |
| AVG Volume (30 Days) | 228.1K | ★ 321.6K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.01% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.10 | $12.25 |
| 52 Week High | $29.05 | $15.75 |
Technical Indicators
Market Signals| Indicator | ODTX | NFJ |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 33.36 |
| Support Level | $15.73 | $14.06 |
| Resistance Level | $19.60 | $15.24 |
| Average True Range (ATR) | 1.35 | 0.22 |
| MACD | 0.31 | -0.02 |
| Stochastic Oscillator | 65.85 | 4.85 |
Price Performance
Historical ComparisonAbout ODTX Odyssey Therapeutics Inc. Common Stock
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. It pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.